Skip to content

13F-HR filed by Octagon Capital Advisors LP

Octagon Capital Advisors LP filed this 13F-HR for the quarter ended 2020-12-31, filed 2021-02-16, with 31 holding rows worth $288,474,000.

Accession
0001214659-21-001943
Filed
2021-02-16
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q4 2020

A holdings report, 31 entries on the cover page, a total value of $288,474,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $288,474,000 with VALUE read as thousands by filing date, 13F file number 028-20958. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
APELLIS PHARMACEUTICALS INC03753U106COM548,374$31,367,000thousands by filing date
NOVABRIDGE BIOSCIENCES44975P103CMN454,550$21,432,000thousands by filing date
CELLDEX THERAPEUTICS INC NEW15117B202COM NEW1,041,398$18,245,000thousands by filing date
CURIS INC231269200COM2,200,000$18,018,000thousands by filing date
4D MOLECULAR THERAPEUTICS INC COM35104E100Stock377,777$15,659,000thousands by filing date
PMV PHARMACEUTICALS INC69353Y103COM250,000$15,378,000thousands by filing date
ARVINAS INC04335A105COM178,500$15,160,000thousands by filing date
GOSSAMER BIO INC COM38341P102Stock1,563,138$15,116,000thousands by filing date
ACCELERON PHARMA INC00434H108COM112,363$14,376,000thousands by filing date
CHEMOCENTRYX INC16383L106COM225,076$13,937,000thousands by filing date
CARDIFF ONCOLOGY INC14147L108COM650,000$11,694,000thousands by filing date
AVIDITY BIOSCIENCES INC COM05370A108Stock430,041$10,975,000thousands by filing date
DYNE THERAPEUTICS INC COM26818M108Stock481,538$10,112,000thousands by filing date
TAYSHA GENE THERAPIES INC877619106COMMON STOCK320,440$8,504,000thousands by filing date
ARCUS BIOSCIENCES INC03969F109COM300,000$7,788,000thousands by filing date
CALLIDITAS THERAPEUTICS AB SPONSERED13124Q106ADS200,000$6,724,000thousands by filing date
FIBROGEN INC31572Q808COM146,014$5,416,000thousands by filing date
KINIKSA PHARMACEUTICALS LTDG5269C101COM CL A295,238$5,217,000thousands by filing date
REVOLUTION MEDICINES INC COM76155X100Stock126,136$4,994,000thousands by filing date
KURA ONCOLOGY INC COM50127T109Stock150,000$4,899,000thousands by filing date
IVERIC BIO INC46583P102COM680,036$4,699,000thousands by filing date
MOONLAKE IMMUNOTHERAPEUTICSG4444C102COM400,000$4,548,000thousands by filing date
KRONOS BIO INC50107A104COM146,173$4,366,000thousands by filing date
JIYA ACQUISITION CORP47760M102CMN300,000$3,090,000thousands by filing date
VIELA BIO INC.926613100Common Stock85,409$3,072,000thousands by filing date
INVENTIVA SA46124U107ADS200,000$2,900,000thousands by filing date
ARCUTIS BIOTHERAPEUTICS INC03969K108COM100,000$2,813,000thousands by filing date
NGM BIOPHARMACEUTICALS INC62921N105COM75,227$2,279,000thousands by filing date
ACLARIS THERAPEUTICS INC COM00461U105Stock350,000$2,265,000thousands by filing date
KADMON HLDGS INC48283N106COM434,114$1,802,000thousands by filing date
AXSOME THERAPEUTICS INC. COM05464T104Stock20,000$1,629,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001214659-21-001943this filing2021-02-16acceptance time not in the bulk data set